Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

paving the way for spotting and treating neurodegenerative diseases like multiple sclerosis and Parkinson's disease at earlier stages. The answer to this is not as simple as you might think. New ...

Research led by the University of Michigan has provided compelling evidence that could solve a fundamental mystery in the ...

Research has provided compelling evidence that could solve a fundamental mystery in the makeup of fibrils that play a role in Alzheimer's, Parkinson's and other neurodegenerative diseases.

Scientists have identified a relationship between ancient viral DNA and susceptibility to neurodegenerative diseases like ...

Researchers have found that a compound derived from used coffee beans shows promise in protecting brain cells from damage ...

Researchers have long known fibrils—tiny tendrils assembled from invisibly small building blocks called amyloid proteins—are connected to a number of neurodegenerative diseases. But important ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

A study from Kumamoto University reveals that G-quadruplex RNA structures facilitate the aggregation of α-synuclein, a ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.